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Introduction: The latest WHO guidelines recommend initiating antiretroviral therapy
(ART) at CD4 cell counts less than 350cells/ml. However, donors and national
governments are reluctant to support implementation owing to uncertainty regarding
feasibility and relative beneﬁt. Lesotho has supported earlier initiation since 2008. We
assessed outcomes comparing early (CD4 cell counts >200cells/ml) and late (CD4 cell
counts  200cells/ml) initiation.
Methods: We describe survival probability among patients initiating ART at CD4 cell
counts 200 or less and more than 200cells/ml and assess associations between baseline
CD4 cell counts and mortality, morbidity, loss to follow-up and hospitalization using
Cox regression adjusting for confounders identiﬁed a priori.
Results: Our analysis included 1177 patients; median age was 38 years and the
majority (67%) were women. Median time on ART for the overall cohort was 506
days (interquartile range 396–608). Five hundred and thirty eight patients initiated ART
at a CD4 cell count 200cells/ml or less (interquartile range 54–160) and 639 patients
initiated at CD4 cell count more than 200cells/ml (interquartile range 238–321). In
multivariate analysis, we found that patients initiating at CD4 cell count more than
200cells/ml were 68% less likely to die (adjusted hazard ratio 0.32, 95% conﬁdence
interval 0.20–0.50), and 39% less likely to be lost to follow-up (adjusted hazard ratio
0.61, 95% conﬁdence interval 0.43–0.87). Initiating ART at CD4 cell count more than
200cells/ml was also associated with a 27% reduction in the rate of incident morbidity
(adjusted hazard ratio 0.73, 95% conﬁdence interval 0.65–0.82) and a 63% decreased
rateofhospitalization(adjustedhazardratio0.37, 95%conﬁdenceinterval0.19–0.73).
Conclusion: Earlier initiation is feasible in a low resource, high HIV prevalence setting,
and provides important beneﬁts in terms of reduced mortality, morbidity, retention and
hospitalization. Donors should fully support the implementation of the latest WHO
recommendations.  2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
In November 2009, the WHO revised its guidelines
for antiretroviral therapy (ART) to recommend that
ART should be started earlier: although previous
WHO guidelines recommended that adolescent and
adult patients should begin therapy when their CD4
cell count drops to or below 200cells/ml[ 1 ] ,t h el a t e s t
recommendations, released in November 2009,
recommend that patients should start ART at a
CD4 cell count 350cells/ml or less regardless of the
presence or absence of clinical symptoms [2]. This
recommendation is in line with guidelines for Western
settings [3–5] and recent evidence from randomized
trials [6] and cohort studies [7]. However, uncertainty
remains around the feasibility and relative beneﬁt of
earlier initiation in resource-limited settings, and
international donors are equivocal in their willingness
to provide funding to support developing countries to
provide treatment in line with the latest WHO
recommendations [8]. As a consequence, implementa-
tion of the new WHO recommendations is varied.
Malawi has announced a move towards initiation at
less than 350cells/ml but has yet to implement these
recommendations; South Africa and Botswana’s latest
guidelines limit early initiation to speciﬁc patient
groups [patients with tuberculosis (TB) or pregnant
women]; Mozambique has implemented an inter-
mediate threshold of 250cells/ml; others, such as
Ethiopia, have yet to revise their guidelines beyond
200cells/ml[ 9 ] .
Lesotho is a poorly resourced country in southern Africa
with the third highest HIV prevalence in the world, with
adultprevalence estimatedat23%.Thecountryadopteda
policy of earlier initiation of ART for adult patients with
lessthan350cells/mlorWHOstageIII/IVirrespectiveof
CD4 cell count in late 2007 [10]. This provides an
opportunity to assess the impact of the latest WHO
recommendations in a routine programme setting. We
assess outcomes comparing early (CD4 cell count
>200cells/ml) and late (CD4 cell count  200cells/ml)
initiation.
Methods
Study setting
In 2006, Me ´decins Sans Frontie `res (MSF) and the
Ministry of Health and Social Welfare established a
decentralized HIV/AIDS care and treatment pro-
gramme at the primary healthcare level in the Scott
catchment area, serving a population of approximately
200000 people. ART services were provided from
March 2006, and by the beginning of 2010 the
programme had cumulatively enrolled a total of 6081
patients on ART. Treatment is provided across 14
primary care health centres and one district hospital,
each staffed by nurses who initiate and manage ART
with the support of a mobile clinical supervision team;
complicated cases are referred to the 102-bed district
hospital, with all transfers recorded in the health centre
ﬁles [11]. After initiation, patients present at the
health centres on a monthly basis for check up and ART
reﬁlls.
Outcome ascertainment
Mortality out-of-facility was reported to clinic staff by
relatives, village leaders, community health workers, and
facilityTB/HIVlaycounselorswhowereresponsiblefor
defaulter tracing. Defaulter tracing was done within a
few days of a patient missing an appointment such that
early mortality among those lost to follow-up was
documented within a month of a missed appointment.
Incident morbiditieswere recorded in the clinicﬁles and
veriﬁed by clinicians and crosschecked against corre-
sponding prescriptions. All hospitalizations documented
from the clinic were crosschecked against hospital
admission notes.
Data management and analysis
Data were recorded at each clinic by nurses in paper-
based registers based on the WHO registers. Variables
were extracted by a team of three clinicians and entered
into an Access database, then exported into STATA
(version 11) (StataCorp LP, Texas, USA) for analysis. All
patients aged at least 5 years initiating ART from 1
January 2008 to 31 December 2008 were included in
the analysis and followed until 31 December 2009.
Patients were categorized according to their baseline
CD4 cell count (deﬁned as a CD4 cell count measure
within 30 days of ART initiation) according to
two groups: early initiation (>200cells/ml) and late
initiation ( 200cells/ml). Baseline characteristics were
described using medians and interquartile ranges (IQRs)
for continuous variables and counts and percentages for
categorical variables. We used Kaplan–Meier estimates
to describe the cumulative probability of progression to
death, morbidity, loss to follow-up (deﬁned as missing
an appointment for more than 90 days) and hospital-
ization according to CD4 cell count at initiation.
Multivariate Cox proportional hazards models were
used to estimate hazard ratios adjusting for potential
confounders deﬁned a priori using the following
variables: sex (male or female), age ( 40 or >40 years),
pregnant at initiation, TB at initiation and migrant
worker (yes/no). Hazard proportionality was assessed by
analysis of scaled Schoenfeld residuals. The potential
effect of misclassiﬁcation of mortality among patients
lost to follow-up was assessed in a sensitivity analysis
using a competing risks framework [12], and an analysis
that considered all patients lost to follow-up as dead.
All reported P values are exact and two-tailed, and
for each analysis P less than 0.05 was considered
signiﬁcant.
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The analysis was approved by MSF’s independent Ethics
Review Board.
Results
Our sample included 1228 patients. Median age was
38 years and the majorityof patients (67%) werewomen.
Median time on ART for the overall cohort was
506 days (IQR 396–608). Five hundred and thirtyeight
patients initiated ART late, at a CD4 cell count
200cells/ml or less (IQR 54–160) and 639 patients
initiated early, at CD4 cell count more than 200cells/ml
(IQR 238–321). Fifty-one patients had no baseline
CD4 cell count recorded and were excluded from all
further analyses. Patient characteristics are summarized
in Table 1.
Rates of mortality, morbidity, hospitalization and loss to
follow-up according to early or late ART initiation are
described in Fig. 1a-d. In multivariate analysis of the risk
of death according to CD4 cell count group at initiation,
we found that patients initiating ARTearly were 68% less
likely to die [aHR (adjusted hazard ratio) 0.32, 95%
conﬁdence interval (CI) 0.20–50] and 39% less likely to
be lost to follow-up (aHR 0.61, 95%CI 0.43–0.87)
compared with those initiating late (Table 2). The
competing risk regression did not alter our mortality
estimate in either magnitude or signiﬁcance (subhazard
ratio 0.33, 95%CI 0.21–0.52). In a second sensitivity
analysis that treated all loss to follow-up as deaths, the
overall mortality estimate was only marginally reduced
(aHR 0.47, 95%CI 0.36–0.62). We also assessed the
possibilitythatdifferencesbetweengroupsweredrivenby
high mortality among patients with a very low CD4 cell
count in a sensitivity analysis that omitted patients who
had a CD4 cell count 100cells/ml or less; this analysis did
not importantly affect the magnitude or direction of the
observed difference in mortality (aHR 0.45; 95%CI
0.26–0.77).
In our multivariate analysis of risk of morbidity, we
assumed that any disease event would represent an
additional burden to the health service. Disease events
included TB, cryptococcal meningitis, HIV malignancy,
herpes simplex virus, toxoplasmosis, oesophageal thrush,
oral thrush, Pmeumocystis carinii pneumonia, diarrhoea,
rash and respiratory tract infections. We found that
initiating ARTearly was associated with a 27% reduction
in the risk of incident morbidity (aHR 0.73; 95%CI
0.65–0.82).
Finally, in our multivariate analysis assessing risk of
hospitalization, we found that earlier initiation was
associated with a 63% decreased risk of hospitalization
(aHR 0.37; 95%CI 0.19–0.73) (Table 2). TB was the
mainreasonforhospitalizationamongthoseinitiatinglate
(accounting for 37% of hospital admissions vs. 21.4% for
those initiating early).
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Table 1. Baseline characteristics of patients initiating antiretroviral therapy.
Total patients
(n¼1228)
Patients with CD4
 200 (n¼538)
Patients with
CD4 >200
(n¼639)
Patients with
missing baseline
CD4 (n¼51)
CD4, median (IQR) 212 (120–285) 111 (54–160) 280 (238–321) –
Sex
Female 801 (66.7%) 324 (60.2%) 470 (73.6%) 27 (52.9%)
Male 400 (33.3%) 214 (39.8%) 169 (26.5%) 24 (47.1%)
Age, median (IQR) 38.4 (30.3–48.5) 39.1 (30.8–47.3) 37.7 (29.4–49.7) 40.1 (29.1–53.1)
Pregnant at initiation
M
Yes 84 (10.2%) 26 (8.0%) 56 (11.9%) 2 (7.4%)
No 737 (89.8%) 298 (92.0%) 414 (88.1%) 25 (92.6%)
Migrant
No 1079 (87.9%) 469 (87.2%) 565 (88.4%) 45 (88.2%)
Yes 149 (12.1%) 69 (12.8%) 74 (11.6%) 6 (11.8%)
Median duration of follow up
(days), median (IQR)
506 (396–608) 487 (365–587) 522 (424–614) 640 (330–673)
Regimen
Tenofovir 608 (49.6%) 272 (50.6%) 316 (49.5%) 20 (39.2%)
Zidovudine 275 (22.4%) 97 (18.0%) 169 (26.5%) 9 (17.7%)
Stavudine 345 (28.1%) 169 (31.4%) 154 (24.1%) 22 (43.1%)
TB at initiation
No 1019 (83.0%) 409 (76.0%) 573 (89.7%) 37 (72.6%)
Yes 209 (17.0%) 129 (24.0%) 66 (10.3%) 14 (27.5%)
IQR, interquartile range; TB, tuberculosis.
MDenominator includes only women.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 1. (a-d) Kaplan–Meier plots showing the probability and rates of adverse events according to CD4 cell count group at ART
initiation. ART, antiretroviral therapy; CI, conﬁdence interval; PYS, person years.
Table 2. Multivariate analysis of risk of adverse outcomes comparing early and late antiretroviral initiation.
Mortality Loss to follow-up Incident morbidity Hospitalization
Adjusted hazards
ratio (95%CI) P
Adjusted hazards
ratio (95%CI) P
Adjusted hazards
ratio (95%CI) P
Adjusted hazards
ratio (95%CI) P
CD4 cell count group
 200 cells/ml1 1 1 1
>200 cells/ml 0.32 (0.20–0.50) <0.001 0.61 (0.43–0.87) 0.006 0.73 (0.65–0.82) <0.001 0.37 (0.19–0.73 0.004
Sex
Female 1 1 1 1
Male 0.90 (0.34–2.38) 0.83 0.37 (0.20–0.68) 0.001 0.74 (0.64–0.85) <0.001 1.07 (0.56–2.06) 0.83
Age
<40 1 1 1 1
>40 1.68 (1.10–2.59) 0.017 0.52 (0.34–0.80) 0.002 1.04 (0.93–1.17) 0.16 1.44 (0.77–2.68) 0.25
Pregnant at initiation
Yes 1 1 – – – –
No 0.76 (0.30–1.97) 0.57 0.52 (0.34–0.80) 0.012
Migrant
N o ––1 ––– –
Yes 2.77 (1.83–4.19) <0.001
TB at initiation
Yes – – – – 1 1
No 1.00 (0.85–1.18) 0.99 0.87 (0.38–2.00) 0.74
Schoenfelds p 0.54 0.50 0.18 0.50
– variable was not adjusted for in the model. CI, conﬁdence interval; TB, tuberculosis.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Conclusion
Our study, using routinely collected clinic data from a
nurse-led, community-based ART programme, provides
further evidence of the beneﬁts of early initiation at CD4
cell count less than 350cells/ml for both the patients and
health services.
The signiﬁcant reduction in mortality and morbidity
observed in our cohort is in line with data from other
studies. A recent randomized trial conducted in Haiti
found a four-fold difference in mortality and a two-fold
difference in incident TB among patients who initiated
ART early compared with those whose treatment was
deferred [6], and an analysis of data from 18 treatment
cohorts in Europe and North America found a substantial
reduction in opportunistic infections and serious non-
AIDS clinical events associated with early initiation (CD4
cell counts <250 vs. CD4 cell counts >350cellsml) [13].
The substantial mortality reduction we observed likely
reﬂects the high prevalence of severe opportunistic
infections in developing country cohorts, in particular
TB [14], and the poorer availability of secondary care
services common to many developing country settings.
ThatTBwasamajorcauseofhospitalizationamongthose
patientsinitiatingARTlateisofconcernforbothmedical
and public health reasons, and serves to highlight the
importance of providing integrated TB and HIV services
insettingslikeLesothowhereratesofcoinfectionarehigh
[15].
We found that early initiation was associated with a
substantial decrease in the risk of defaulting. This ﬁnding
isconsistentwith ﬁndingsfromarecentsystematicreview
[16], although some studies have found higher defaulting
among patients initiating ARTat higher CD4 cell counts
[17,18] with the explanation put forward that patients
value their medication less if they have not experienced
illness prior to ART. We would suggest that this concern
depends to a considerable extent on how patients are
counseled at initiation and their understanding of the
beneﬁts of early initiation. Implementation of the new
WHOguidelines should thus be accompanied byadapted
adherence counseling for patients, as was the case in the
Lesotho programme.
Recent modeling has suggested that earlier initiation of
ART at CD4 cell count less than 350cells/ml, while
initially increasing the need for ART and thus costing
more, will be cost effective over time owing to a
reduction in illness. The beneﬁts of early initiation found
inourcohortwereasgoodasorgreater thantheestimates
used in this costing model, suggesting that early initiation
may even be more cost effective than forecast [19].
A related advantage noted by programme staff was that
the associated reduction in clinical complications was
supportive of the nurse-led approach to ART delivery
thatispracticedinLesothoandpromotedbytheWHOas
away to overcome the lackof doctorsworking at primary
care level in resource-limited settings [20].
Our study is subject to several biases, in particular lead-
time bias, which recognizes that a number of unseen
AIDS-related mortality and morbidity will have occurred
among patients not started at CD4 cell counts between
200 and 350cells/ml. Statistical methods exist to allow for
partial adjustment for lead-time bias by modeling the
estimate of mortality among those unseen patients who
would have died before reaching the threshold for late
initiation [21]. We do not have reliable estimates for these
events in our population so have not attempted such an
adjustment. However, published estimates of mortality
among untreated individuals with higher CD4 from
elsewhere in southern Africa [22,23] suggest that such
bias would likely lead to an underestimation of the true
difference. Studies from Western settings that either
adjusted for lead-time bias [24] or avoided it in the study
design [25] report higher mortality compared with
previous studies in similar populations. A second source
of potential bias is related to misclassiﬁcation of mortality
owing to defaulting. In reports of vital status ascertain-
ment among patients lost to follow-up it has been found
that a substantial proportion are in fact dead [26]. We
assessed this in sensitivity analyses and did not ﬁnd an
important difference to our mortality effect estimate, but
recognize that such misclassiﬁcation will exist. Given that
loss to follow-up is higher in the group who initiated late,
we can expect that this bias would also lead to an
underestimation of effect. For both these reasons, the
mortality reduction resulting from early initiation
reportedinthiscohortcanbeconsideredasaconservative
underestimation of the true difference. Another limita-
tion,commontoanyobservationalstudy,isthatevenafter
adjustment for potential confounders, residual confound-
ing may exist. Finally, it is important to note that data on
hospitalizationarecontext-speciﬁc.Inoursettingpatients
may live over half a day’s travel from the hospital, and
some are unable to afford the associated transport costs.
Although we do not expect that such barriers are
differential and so unlikely to affect the difference
between CD4 cell count groups, hospitalization rates will
likely be different in other settings where access to
hospital care is less problematic.
In conclusion, far from overwhelming health services and
increasing inequities as some have suggested [27], early
initiation in Lesotho has been supportive of a simpliﬁed
approach to delivering ARTat the primary care level. The
reducedriskofillnessanddeathaffordedbyearlyinitiation
has translated into programme-level gains by resulting in a
cohort of patients who require less intensive clinical
support.Thisisofconsiderablebeneﬁtinresource-limited
settings like Lesothowhere human resources for health are
inadequate and the majorityof patient care is delivered by
nurses. In this way, earlier initiation is not only important
from a clinical perspective, but also supports broader
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programme objectives in terms of service efﬁciencies and
equitable access to treatment [28].
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